Phase II trial of ifosfamide+cisplatinum in advanced ovarian cancer

Australian and New Zealand Journal of Medicine

Volumn 28, Issue 3, 1998, Pages 403-409

  Aziz, Z ^a,b   Zahid, M ^a   Ud Din Ahmed, Z ^a   Arshad, T ^a  

^a ALLAMA IQBAL MEDICAL COLLEGE   (Pakistan)

^b JINNAH HOSPITAL   (Pakistan)

Author keywords

Cisplatinum; Ifosfamide; Intraperitoneal chemotherapy; Ovarian cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LAPAROTOMY; OVARY CANCER; SECOND LOOK SURGERY; TREATMENT OUTCOME;

EID: 0031856828     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1998.tb01975.x     Document Type: Conference Paper

References (31)

1. Ozols RF, Rubin SC, Dembo AJ, Robboy S. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC (Eds). Philadelphia: JB Lippincott, 1992, pp 731-782.
2. Gruppe Interegionale Cooperativo Oncologico Ginecologia: Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 1987; ii: 353-9.
3. Neijt JP. Ten Bokkel Huinink WW, Van der Burg ME et al. Randomized trial comparing two combinations. J Clin Oncol 1987; 5: 1157-68.
4. De la Garza J, Cardenas J. Ifosfamide in the treatment of ovarian cancer (Abstr.: 428). Proceedings of the 13th International Cancer Congress, 1982, Vol: 76, Seattle.
5. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9.
6. Sutton G. Ifosfamide and mesna in epithelial ovarian carcinoma. Gynecol Oncol 1993; 51: 104-8.
7. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, Boyes DA. Ovarian carcinoma: A multivariate analysis of prognostic factors. Obstet Gynecol 1985; 65: 264-9.
8. Einhorn N, Nilsson B, Sjoval K. Factors influencing survival in carcinoma of the ovary. Cancer (1985); 55: 2019-25.
9. Makar APh, Backelandt M, Trope CG, Kristensen GB. The prognostic significance of residual disease, FIGO Substage, Tumor Histology and Grade in Patients with FIGO Stage III Ovarian Cancer Gynaecologic Oncology 1995; 56: 175.
10. Alberts DS, Green S, Hannigan EV et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide. Final report by the Southwest Oncology Group of a phase III randomized trial in stages III (suboptimal) and IV ovarian cancer. J Clin Oncol 1992; 10: 706-17.
11. Swenerton K, Fraser R, Stuart G et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992; 10: 718-26.
12. McGuire WP, Hoskins WJ, Brady MF, Kucera PR et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-5.
13. Norpoth K. Studies on the metabolism of isophosphamide (NSC-109724) in man. Cancer Treatment Rep 1976; 60: 437-43.
14. Perez RP, Hamilton RC, Ozols RF. Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol Ther 1990; 48: 19-27.
15. Hamilton TC. Ovarian cancer Part I. Curr Probl Cancer 1992; 16: 5-57.
16. Sutton GP, Blessing JA, Homesley HD, Berman ML, Malfetano J. Phase II trial of ifosfamide and mesna in advanced ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 1989; 7: 1672-6.
17. Bruhl P, Gunther U, Hosfer-Janker K et al. Results obtained with fractionated ifosfamide massive dose treatment in generalized malignant tumors. Int J Clin Pharmacol 1976; 14: 29-30.
18. Fanning J, Hilgers RD, Hutson E. Carboplatin, etoposide, and ifosfamide as second-line treatment for ovarian cancer. Am J Clin Oncol 1994; 17: 335-7.
19. Perren TJ, Wiltshaw E, Harper P et al. A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group. Br J Cancer 1993; 68: 1190-4.
20. Lorusso V, Catino A, Leone B, Rabinovich M, Gargano G et al. Carboplatinum plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study. J Clin Oncol 1993, 11: 1952-6.
21. Araujo CE, Cervellino JC, Pirisi C, Pannunzio O, Callegari J. Chemotherapy with high dose ifosfamide/mesna plus cisplatin for the treatment of ovarian cancer: a study of the Grupo de Estudio y Tratamiento Latino-Americano del Cancer. J Surg Oncol 1991; 46: 198-202.
22. Malkasian GD, Melton LJ, O'Brien PC, Greene MH. Prognostic significance of histologie classification and grading of epithelial malignancies of ovary. Am J Obstet Gynecol 1984; 274: 274-82.
23. Van der Burg MEL, van Lent M, Kobierska A et al. Intervention debulking surgery does improve survival in advanced epithelial ovarian cancer, An EORTC Gynecological Cancer Cooperative Group (GCCG) study. Proc Am Soc Clin Oncol 1993 12: 258 (Abstr. 818).
24. Markman M, Reichman B, Hakes T et al. Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer 1993; 71: 1565-70.
25. De Gregorio MW, Lum BL, Holleran WM et al. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol 1986; 18: 235-8.
26. O'Dwyer PJ, LaCreta FP, Daughterly P et al. Phase I pharmacokinetic study of intraperitoneal etoposide. Cancer Res 1991; 51: 2041-6.
27. Pujade E, Guastalla JP, Colombo N, Devillier P et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second look laparotomy. J Clin Oncol 1996; 14: 343-50.
28. Speyer JL, Beller U, Colombo N et al. Intraperitoneal carboplatin: favourable results in women with minimal residual ovarian cancer after cisplatin therapy. J Clin Oncol 1990; 8: 1335-41.
29. Kirmani S, Lucas WE, Kim S et al. A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma. J Clin Oncol 1991; 9: 649-57.
30. Menczer J, Ben-Baruch G, Modan M et al. Intraperitoneal cisplatin chemotherapy versus abdomino-pelvic irradiation in ovarian carcinoma patients after second-look laparotomy. Cancer 1989; 63: 1509-13.
31. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Vogel S et al. 760 Phase III Study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) vs IV CDDP/IV CPA in patients (PTS) with optimal disease stage III ovarian cancer: A SWOG-GOG-ECOG intergroup study (INT 0051). Proceedings ASCO 1995; 14: 273 (Abstr. 76).